Announcement • Jul 02

Revolution Medicines, Inc. Presents Phase 1/2 Clinical Data For Zoldonrasib Combination Regimens In Patients With RAS G12D Metastatic Pancreatic Cancer

Revolution Medicines, Inc. announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The results include zoldonrasib in combination with standard of care chemotherapy in previously untreated patients and zoldonrasib in combination with daraxonrasib, the company’s oral RAS(ON) multi-selective inhibitor, in previously treated patients. RMC-GI-102 (NCT06445062) is an ongoing Phase 1/2 trial evaluating zoldonrasib 1200 mg once daily in combination with investigator's choice of standard of care chemotherapy in patients with previously untreated metastatic RAS G12D PDAC. Investigator's choice of chemotherapy includes modified FOLFIRINOX (mFFX) or gemcitabine plus nab-paclitaxel (GnP). As of the February 8, 2026 data cutoff, the trial enrolled 41 patients in the zoldonrasib plus mFFX arm and 40 patients in the zoldonrasib plus GnP arm. Zoldonrasib demonstrated a manageable safety and tolerability profile in combination with standard chemotherapy. The safety profile of zoldonrasib in combination with chemotherapy was broadly consistent with the established profiles of each respective chemotherapy regimen. Grade 3 or greater treatment-related adverse events (TRAEs) occurred in 61% of patients who received the zoldonrasib plus mFFX and 80% of patients who received zoldonrasib plus GnP. The most common Grade 3 or greater TRAEs with zoldonrasib plus mFFX were decreased neutrophil count (37%), anemia (12%), and platelet count decreased (7%). The most common Grade 3 or greater TRAEs with zoldonrasib plus GnP were decreased neutrophil count (35%), anemia (28%), and fatigue (25%). No Grade 5 TRAEs were reported in either arm. The mean dose intensity was 86% with zoldonrasib plus mFFX and 90% with the zoldonrasib plus GnP. In the trial, zoldonrasib with chemotherapy showed compelling antitumor activity, with an objective response rate (ORR) of 82% (95% confidence interval [CI]: 60, 95) and disease control rate (DCR) of 96% (95% CI: 77, 100) in the mFFX population, and an ORR of 61% (95% CI: 42, 78) and DCR of 90% (95% CI: 74, 98) in the GnP population. These preliminary safety and clinical activity data support the ongoing RASolute 305 pivotal trial (NCT07621718), a global, randomized, double-blind placebo-controlled Phase 3 clinical trial evaluating zoldonrasib plus investigator’s choice of standard of care chemotherapy compared with placebo plus investigator’s choice of chemotherapy in patients with previously untreated metastatic RAS G12D PDAC. RMC-9805-001 (NCT06040541) is a Phase 1 trial evaluating zoldonrasib 1200 mg once daily plus daraxonrasib 300 mg once daily in advanced solid tumors with RAS G12D mutations. As of the February 9, 2026 data cutoff, 60 patients with RAS G12D metastatic PDAC who had previously received one or more prior lines of therapy were treated with the combination. Zoldonrasib plus daraxonrasib demonstrated a manageable safety and tolerability profile that was broadly consistent with the established profile of daraxonrasib monotherapy. Grade 3 or greater TRAEs occurred in 35% of patients who received the combination. Among TRAEs occurring in 10% or more of all patients, the most common Grade 3 or greater events were rash (12%), anemia (10%), and stomatitis/mucositis (7%). Few patients discontinued due to TRAES; 2% discontinued zoldonrasib and 5% discontinued daraxonrasib. The mean dose intensity was 88% for zoldonrasib and 76% for daraxonrasib. The zoldonrasib plus daraxonrasib combination demonstrated compelling antitumor activity in patients with previously treated metastatic PDAC. In the second line cohort (2L) (N=30), the ORR was 50% (95% CI: 31–69) and DCR was 97% (95% CI: 83–100). Median progression-free survival (PFS) in the 2L cohort was 9.6 months (95% CI: 7.1–NE), with a 6-month PFS rate of 71%. Median overall survival (OS) in the 2L cohort was not yet estimable, with a 6-month OS rate of 89%. In the third line and beyond (3L+) cohort (N=30), the ORR was 47% (95% CI: 28–66) and DCR was 90% (95% CI: 74–98). Median PFS in the 3L+ cohort was 7.6 months (95% CI: 4.6–10.5), with a 6-month PFS rate of 59%. Median OS in the 3L+ cohort was 10.5 months (95% CI: 6.7–NE), with a 6-month OS rate of 82%. These safety and clinical activity data support the planned pivotal global, Phase 3 RASolute 309 clinical trial of zoldonrasib plus daraxonrasib versus GnP in patients with previously untreated RAS G12D metastatic PDAC. Zoldonrasib is an investigational, oral RAS(ON) G12D-selective covalent tri-complex inhibitor. RAS G12D is the most prevalent RAS mutation, accounting for 29% of all RAS cancers. Across tumor types, approximately 61,000 new patients with RAS G12D cancers are estimated each year in the U.S., and no targeted therapy is currently approved for these patients. Zoldonrasib is currently being evaluated as a monotherapy and in combination with other therapies, including with Revolution Medicines’ RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236), as well as standard of care regimens in lung and gastrointestinal cancers. Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent tri-complex inhibitor. Daraxonrasib is designed to target cancers driven by a broad range of common RAS genotypes, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. Daraxonrasib is being advanced through a global Phase 3 registrational program comprising four trials, including the completed RASolute 302 trial and three additional trials in patients with PDAC and metastatic RAS mutant NSCLC.

Announcement • Apr 22

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Revolution Medicines, Inc. announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago. Revolution Medicines recently reported an unprecedented overall survival (OS) benefit with daraxonrasib from the RASolute 302 clinical trial. These topline results showed that daraxonrasib taken once daily orally met all primary and key secondary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and OS compared with standard of care intravenous cytotoxic chemotherapy. The presentation will describe these findings, as well as additional analyses of efficacy and safety. The following additional Revolution Medicines–sponsored abstracts have been accepted for online publication: Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: a real-world analysis (Abstract #e16383); Patient characteristics, treatment patterns, and survival in a metastatic pancreatic adenocarcinoma U.S. patient population (Abstract #e16379); Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) (Abstract #e15104). RASolute 302 (NCT06625320) is a global, randomized Phase 3 registrational clinical trial designed to evaluate the efficacy and safety of daraxonrasib as a monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). In the trial, patients were randomized to receive either an oral dose of 300 mg daraxonrasib once daily or investigator’s choice of standard of care cytotoxic chemotherapy. The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with RAS G12 mutations (such as G12D, G12V, and G12R), as well as patients without an identified tumor RAS mutation (wild type). The primary endpoints of RASolute 302 are progression-free survival (PFS), as assessed by a Blinded Independent Central Review, and overall survival (OS) in patients with tumors harboring RAS G12 mutations. Secondary endpoints include PFS and OS in all enrolled patients (the intent-to-treat population) encompassing patients with and without identified tumor RAS mutations, as well as objective response rate, duration of response, and patient-reported quality of life. Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent inhibitor that is not approved by any regulatory authority, including in the United States or Europe. The U.S. Food and Drug Administration (FDA) granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring G12 mutations. In addition, daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the development and review of therapies aligned with U.S. national health priorities. Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC. Daraxonrasib works by suppressing RAS signaling through inhibition of the interaction between both wild-type and mutant RAS(ON) proteins and their downstream effectors. Pancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates indicate that annually approximately 60,000 people will be diagnosed with pancreatic cancer, and about 50,000 people will die from this aggressive disease. Due to the lack of early symptoms and detection methods, approximately 80% of patients are diagnosed with PDAC at an advanced or metastatic stage. It is the most commonly RAS-addicted of all major cancers, and more than 90% of patients have tumors that harbor RAS mutations. Metastatic PDAC remains one of the most common causes of cancer-related deaths in the U.S., with a five-year survival rate of approximately 3%.

Total Shareholder Yield	-5.2%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Segment	Dividend Yield
Company (RVMD)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.0%
Industry Average (Biotechs)	1.9%
Analyst forecast (RVMD) (up to 3 years)	0%

Data	Last Updated (UTC time)
Company Analysis	2026/08/12 12:04
End of Day Share Price	2026/08/12 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Jeffrey Walch	Bernstein
Alec Stranahan	BofA Global Research
null null	Evercore ISI

Revolution Medicines Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Consensus revenue estimates increase by 29%, EPS downgraded

Price target increased by 7.2% to US$222

Revolution Medicines Unveils BeOne Partnership for Cancer Drug Trials and Asian Market Rights

Surge in Compassionate Use for Revolution Medicines’ Pancreatic Cancer Drug Highlights Unmet Need

RVMD: Pancreatic Cancer Survival Data And FDA Review Will Drive Repricing

High Risk, High Reward: Inside The Revolution Medicines Bull Case

Revolution Medicines, Inc. to Report Q2, 2026 Results on Aug 05, 2026

Revolution Medicines Drug Doubles Survival for Pancreatic Cancer Patients in Trial Data

U.S. Food and Drug Administration Accepts New Drug Application For Daraxonrasib Accepted For Review A For Previously Treated Metastatic Pancreatic Cancer of Revolution Medicines, Inc

RVMD: FDA Review And RAS Portfolio Progress Point To Balanced Future

RVMD: Pancreatic Cancer Survival Breakthrough Will Drive Repricing Of Future Prospects

European Medicines Agency Accelerates Daraxonrasib Review as Revolution Medicines Finalizes FDA Submission

Revolution Medicines Posts Strong Phase 1/2 Results for Zoldonrasib in Pancreatic Cancer

Revolution Medicines, Inc. Presents Phase 1/2 Clinical Data For Zoldonrasib Combination Regimens In Patients With RAS G12D Metastatic Pancreatic Cancer

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell 2500 Value Benchmark

Chief Financial Officer notifies of intention to sell stock

RVMD: Survival Breakthrough In Pancreatic Cancer Will Likely Not Justify Current Pricing

Revolution Medicines, Inc. Begins Treating Patients in RASolute 305 Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as First Line Treatment for Patients with Ras G12d Metastatic Pancreatic Cancer

Revolution Medicines Sets New R&D Leadership as Kelsey Prepares for Board Role

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines Oral Therapy Doubles Survival in Advanced Pancreatic Cancer Phase 3 Trial

Revolution Medicines Reports Daraxonrasib More Than Doubles Survival in Advanced Pancreatic Cancer Trial

Revolution Medicines Presents Unprecedented Results from Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

New minor risk - Profitability

Consensus revenue estimates increase by 26%, EPS downgraded

Revolution Medicines, Inc. to Report Q1, 2026 Results on May 06, 2026

Revolution Medicines, Inc., Annual General Meeting, Jun 18, 2026

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Revolution Medicines Presents Updated Phase 1 Clinical Data For Zoldonrasib In Patients With Previously Treated KRAS G12D Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 29%

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 billion.

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $749.999947 million.

Consensus revenue estimates increase by 10%, EPS downgraded

Revolution Medicines Demonstrates Unprecedented Overall Survival Benefit With Daraxonrasib In Pivotal Phase 3 RASolute 302 Clinical Trial

Price target increased by 7.9% to US$140

Revolution Medicines Begins Treating Patients In Phase 3 RASolute 303 Trial Evaluating Daraxonrasib As First Line Treatment For Patients With Metastatic Pancreatic Cancer

Late Stage RAS Oncology Pipeline Will Reshape Long Term Cancer Treatment Options

Late Stage RAS Oncology Pipeline Will Face Heavy Costs Yet Eventually Support Stable Long Term Outlook

Price target increased by 9.4% to US$133

RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity

Consensus revenue estimates increase by 53%, EPS downgraded

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Price target increased by 8.4% to US$122

JND Legal Administration Announces Proposed Settlement of Stockholder Class Action Involving CMLS Holdings III LLC; Corvex Management LP; Casdin Capital, LLC; Revolution Medicines, Inc

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

New minor risk - Share price stability

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Price target increased by 10% to US$91.89

Chief Operating Officer exercised options and sold US$4.7m worth of stock

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Revolution Medicines, Inc. Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

CEO, President & Chairman notifies of intention to sell stock

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. Reiterates Earnings Guidance for Full Year 2025

Revolution Medicines, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

President of Research & Development exercised options and sold US$1.1m worth of stock

Revolution Medicines, Inc. Receives Voucher for Daraxonrasib (Rmc-6236) Under Fda Commissioner's National Priority Voucher Pilot Program

Revolution Medicines, Inc. Announces Executive Appointments

President of Research & Development exercised options and sold US$5.0m worth of stock

Consensus revenue estimates fall by 86%

Revolution Medicines, Inc. Provides Pipeline Updates

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2025

Insufficient new directors

Revolution Medicines, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Revolution Medicines, Inc. Announces Publication of A Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, A Ras(On) G12d-Selective Inhibitor

Revolution Medicines, Inc. Announces FDA Breakthrough Therapy Designation for Elironrasib

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell 2000 Value Index

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Revolution Medicines, Inc. Announces Resignation of Barbara Weber as Director, Member of the Board’S Nominating and Corporate Governance Committee and Member of the Board’S Research & Development Committee, Effective June 18, 2025